

FOI 4077

Intra-Vitreous Injections or Implants

1. How many of the following intra-vitreous injections/implants has your Trust administered in the four-month period from January to April 2026:

- * Aflibercept – Eylea- NIL
- * Aflibercept – Biosimilar- NIL
- * Bevacizumab- NIL
- * Brolucizumab- NIL
- * Dexamethasone- NIL
- * Faricimab- NIL
- * Fluocinolone acetonide- NIL
- * Ranibizumab - including all Biosimilars- NIL

2. Provide the number of injections/implants by eye condition for the four-month period from January to April 2026:

	Wet Age-Related Macular Degeneration	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept - Eylea	0	0	0	0
Aflibercept - Biosimilar	0	0	0	0
Bevacizumab	0	0	0	0
Dexamethasone	0	0	0	0
Faricimab	0	0	0	0
Fluocinolone acetonide	0	0	0	0
Ranibizumab - including all Biosimilars	0	0	0	0